Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956067 | 0.81 | KDM4E (0.42) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6980139 | 0.75 | KDM4E (0.41) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL2774793 | 0.72 | KDM4E (0.53) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL3530758 | 0.72 | KDM4E (0.53) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL3536193 | 0.72 | KDM4E (0.53) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6533951 | 0.72 | KDM4E (0.53) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6959092 | 0.71 | KDM4E (0.46) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6980214 | 0.71 | CYP1A2 (0.42) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL20979365 | 0.70 | L3MBTL1 (0.41) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6979441 | 0.70 | KDM4E (0.41) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | KDM4E 2805/4885CYP1A2 1375/4885CYP2D6 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.